Table 5.
Incidence of catastrophic drug expenditure (%) of 4 essential medicines in China from 2011 to 2014
| Treatment | Type | Percent of family income | 2011 | 2012 | 2013 | 2014 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Urban | Rural | Urban | Rural | Urban | Rural | Urban | Rural | |||
| Hydrochlorothiazide | Gsa | 7.5% | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| 10.0% | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| 12.5% | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Nifedipine | IBsb | 7.5% | 67.1 | 100.0 | 57.6 | 100.0 | 55.0 | 100.0 | 50.0 | 100.0 |
| 10% | 50.5 | 100.0 | 38.4 | 93.7 | 36.4 | 89.8 | 31.9 | 85.3 | ||
| 12.5% | 37.3 | 92.2 | 28.2 | 90.4 | 28.0 | 83.3 | 24.2 | 77.6 | ||
| Gs | 7.5% | 6.3 | 47.9 | 3.6 | 40.6 | 1.9 | 31.9 | 0.3 | 31.0 | |
| 10.0% | 4.5 | 31.9 | 0.8 | 26.9 | 0.0 | 24.0 | 0.0 | 22.0 | ||
| 12.5% | 2.6 | 25.9 | 0.0 | 24.8 | 0.0 | 16.7 | 0.0 | 12.2 | ||
| Diclofenac | Gs | 7.5% | 22.6 | 78.3 | 17.7 | 73.1 | 14.8 | 60.5 | 13.9 | 63.6 |
| 10.0% | 15.2 | 66.8 | 11.3 | 60.5 | 8.2 | 45.7 | 7.5 | 41.2 | ||
| 12.5% | 11.2 | 54.7 | 7.5 | 54.7 | 4.2 | 36.2 | 3.7 | 33.8 | ||
| Metformin | IBs | 7.5% | 36.0 | 88.8 | 28.0 | 83.8 | 28.0 | 77.6 | 22.0 | 76.9 |
| 10.0% | 21.7 | 80.9 | 17.1 | 74.4 | 18.0 | 67.7 | 14.5 | 58.4 | ||
| 12.5% | 2.4 | 25.4 | 0.0 | 22.8 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Gs | 7.5% | 6.0 | 46.9 | 2.6 | 36.9 | 0.7 | 28.0 | 0.0 | 27.4 | |
| 10.0% | 4.2 | 31.1 | 0.0 | 24.7 | 0.0 | 22.1 | 0.0 | 20.7 | ||
| 12.5% | 16.1 | 69.0 | 12.1 | 69.0 | 12.0 | 55.6 | 9.3 | 45.6 | ||
aGs: Generics
bIBs: Innovator brands